Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a stock with significant upside potential, with multiple analysts maintaining bullish outlooks despite some mixed signals regarding its performance [1][2]. Group 1: Analyst Ratings and Price Targets - H.C. Wainwright raised the target price for SLNO from $110 to $120, indicating strong confidence in the stock's future performance [1]. - Wells Fargo analyst Derek Archila maintained a price target of $106, reflecting a positive sentiment towards the stock [1]. - Cantor Fitzgerald's Kristen Kluska reiterated a Buy rating with a price target of $123, further supporting the bullish outlook [1]. - Wolfe Research cut its price target from $75 to $60 but still maintains a Buy rating, suggesting a potential upside of 41.7% from current levels [2]. Group 2: Company Overview and Market Performance - Soleno Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases, founded in 1999 and based in Redwood City, California [3]. - The company's fourth-quarter sales of Vykat XR exceeded consensus expectations, although there are concerns regarding weaker new patient starts impacting stock performance [2]. - Wolfe Research noted that the current market valuation reflects a bear-case scenario for product uptake, while its base-case outlook anticipates a more moderate decline in new patient starts than currently priced in by the market [2].

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1]. Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's Vykat XR as overpriced and potentially unsafe for children, leading to a share price decline of $5.73, or approximately 7.41%, from $77.36 to $71.64 [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of Vykat XR due to adverse effects was around 8% at the end of Q3 2025. The CEO noted a disruption in the product's launch trajectory following the Scorpion Capital report, resulting in a further share price drop of $16.98, or approximately 26.59%, from $63.85 to $46.87 [4].

Core Viewpoint - Soleno Therapeutics, Inc. is under investigation for potential violations of federal securities laws following negative reports about its product Vykat XR, which has led to significant declines in its stock price [1][2]. Group 1: Company Performance - On August 15, 2025, a report by Scorpion Capital labeled Vykat XR as overpriced and potentially unsafe for children, resulting in a stock price drop of $5.73, or approximately 7.41%, from $77.36 to $71.64 [1]. - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in stock price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [2]. Group 2: Management Response - The CEO of Soleno acknowledged a disruption in the launch trajectory of Vykat XR following the negative report from Scorpion Capital, citing a decrease in start forms and an increase in discontinuations for non-serious adverse events [2].

Core Viewpoint - Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1] Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and potentially unsafe for children, leading to a decline in Soleno's share price by $5.73, or approximately 7.41%, from $77.36 to $71.64 [3] - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [4]

Industry Overview - The drug and biotech sector has shown recovery after a sluggish first half, supported by drug pricing agreements with the Trump administration and renewed M&A activity [1][4] - Innovation in areas such as obesity treatments, gene therapy, inflammation, and neuroscience continues to drive growth, despite challenges like pipeline setbacks and regulatory uncertainty [2][3] Market Performance - The Zacks Medical-Drugs industry has underperformed compared to the Zacks Medical sector and the S&P 500 over the past year, with a collective rise of 1.2% compared to 3.4% and 18.9% respectively [13] - The industry currently holds a Zacks Industry Rank of 90, placing it in the top 37% of 244 Zacks industries, indicating potential for outperformance [12] Valuation Metrics - The industry is trading at a trailing 12-month price-to-sales (P/S) ratio of 2.25, lower than the S&P 500's 6.03 and the Zacks Medical sector's 2.61 [16] Key Companies and Their Prospects - **Ironwood Pharmaceuticals**: Developing apraglutide for short bowel syndrome, with a significant rise in stock price by 178.9% in the past three months and a consensus estimate for 2026 earnings increasing from $0.40 to $0.47 [20][22] - **Rigel Pharmaceuticals**: Sales of Tavalisse rose by approximately 54% in the first nine months of 2025, with a stock increase of 46.7% and a consensus estimate for 2026 earnings rising from $3.70 to $4.30 [24][27] - **Soleno Therapeutics**: Launched Vykat XR for Prader-Willi syndrome, generating around $99 million in sales since April, with a stock decline of 25.7% but a rising consensus estimate for 2026 earnings from $3.10 to $3.59 [29][30] - **Marker Therapeutics**: Focused on next-generation T cell therapies, with a stock increase of 75.5% and a narrowing consensus estimate for 2026 loss per share from $4.92 to $1.86 [33][34] - **Nektar Therapeutics**: Developing rezpegaldesleukin for atopic dermatitis and alopecia areata, with a stock decline of 26.0% but a narrowing consensus estimate for 2026 loss per share from $12.17 to $10.81 [36][38]

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws or unlawful business practices [1] Group 1: Company Overview - Soleno Therapeutics, Inc. is under scrutiny following a report by Scorpion Capital that criticized its only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [2] - The company's stock price experienced significant declines following negative reports and disclosures about Vykat XR, with a drop of approximately 7.41% on August 15, 2025, and a further decline of about 26.59% on November 5, 2025 [2][3] Group 2: Financial Impact - Following the Scorpion Capital report, Soleno's share price fell from $77.36 to $71.64, a decrease of $5.73 per share [2] - On November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price from $63.85 to $46.87, a drop of $16.98 per share [3]

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a promising investment opportunity in the healthcare sector, with a consensus Buy rating from analysts and significant upside potential [1][2]. Analyst Ratings - All 13 analysts covering Soleno Therapeutics have assigned a 'Buy' or equivalent rating, indicating strong market confidence [1]. - Kristen Kluska from Cantor Fitzgerald maintains a 'Buy' rating with a price target of $123, while Kate Dellorusso from LifeSci Capital also holds a 'Buy' rating with a target of $110 [2]. - Wells Fargo's Derek Archila has reduced his price target to $106 from $123 but retains an 'Overweight' rating, citing the potential of Vykat XR as a significant drug for Prader-Willi syndrome [3]. - Wolfe Research initiated coverage with an 'Outperform' rating and a price target of $75, suggesting a nearly 44% upside from the current price, driven by the recent FDA approval of Vykat XR [3]. Company Overview - Soleno Therapeutics, Inc. is a California-based clinical-stage biopharmaceutical company founded in 1999, focusing on novel therapeutics for serious illnesses, specifically offering Diazoxide Choline Extended-Release tablets [4].

Core Insights - Soleno Therapeutics Inc. (NASDAQ: SLNO) experienced a significant decline of 26.59% in stock price, closing at $46.87, marking the fifth consecutive day of losses as investors anticipated strong earnings for Q3 [1][3] - The company reported a net income of $26 million for the third quarter, a 134% improvement from a net loss of $76.6 million in the same period last year, with revenues reaching $66 million [2][3] Company Performance - The strong Q3 results are attributed to increased awareness of the efficacy and safety of Vykat XR, the first and only FDA-approved drug for hyperphagia, particularly within the Prader-Willi Syndrome (PWS) community [3][4] - Vykat XR is positioned as a critical treatment option for patients aged 4 years and older suffering from hyperphagia, addressing a complex patient population with serious co-morbidities [4]

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is highlighted as a promising healthcare stock with significant upside potential, particularly following Goldman Sachs' initiation of coverage with a Buy rating and a price target of $125 [1]. Group 1: Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, specifically targeting neurobehavioral and metabolic disorders [3]. - The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet designed to treat Prader-Willi Syndrome (PWS) [3]. Group 2: Recent Developments - Goldman Sachs anticipates that Soleno Therapeutics' Vykat XR will become a foundational treatment for Prader-Willi syndrome, with expectations for the drug to evolve into a blockbuster franchise [2]. - The recent pullback in the stock price is viewed as an attractive entry point for investors looking to capitalize on the company's potential [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The law firm is reaching out to investors who purchased or acquired Soleno shares and suffered losses, encouraging them to discuss their legal rights [1][2]. - There is no cost or obligation for investors to contact the firm regarding these claims [2]. Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3]. Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5].